Abstract
Transcatheter Aortic valve implantation (TAVI) is a new therapeutic option for inoperable patients or patients at high risk (logistic EURO-Score > 20 %) for conventional aortic valve replacement. The goal of antithrombotic therapy is the minimization of risk of cardioembolic complications. The risk of major stroke after TAVI varies between 1,7 and 8 %. 73 % of all strokes occur after the TAVI-procedure, while 27 % occur during the procedure. Unfractionated heparin (ACT 300 – 350 s) is the recommended peri-procedural antithrombotic therapy. After TAVI dual antiplatelet therapy with 100 mg aspirin and 75 mg clopidogrel should be maintained for 6 months. In case of indication for oral anticoagulation (atrial fibrillation/artificial heart valve), no triple therapy should be administered to these high risk bleeding patients. Antiplatelet monotherapy using clopidogrel in addition to warfarin/phenprocumon is sufficient in these patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
